**Introduction to CRISPR**
CRISPR is an innovative mechanism that is revolutionizing lives and making significant strides in the healthcare sector. CRISPR, an acronym for “Clustered Regularly Interspaced Short Palindromic Repeats,” exists in prokaryotes—tiny, single-celled organisms devoid of organelles. These sequences are situated in the DNA of prokaryotes, which package their genetic material in clusters.
As a gene modification tool, CRISPR is employed to alter specific segments of DNA to combat serious illnesses. It is especially effective as it aids the body in fending off viral infections by integrating the foreign DNA into its own genome, which enables it to recognize and eliminate the virus during subsequent encounters. Notably, when compared to other gene editing techniques, CRISPR offers greater precision and is simpler to program, facilitating a more straightforward sequence redesign process. While many other gene-editing tools generally utilize a single protein, CRISPR employs RNA-guided targeting along with the Cas9 enzyme.
—
**How CRISPR Functions**
CRISPR operates by leveraging a natural defensive method found in bacteria that allows them to detect and eradicate viral threats. Upon a virus infiltrating a bacterial cell (a prokaryote), the bacterium retains a portion of the invader’s DNA within its own genome as a genetic “memory.” This capability permits the bacterium to recognize and respond more adeptly to future invasions.
In gene editing, this mechanism is modified using two essential elements: the Cas9 enzyme, functioning as molecular scissors to sever DNA, and guide RNA, which steers Cas9 to the precise genetic sequence that requires modification. After the targeted DNA is cleaved, the cell’s inherent repair processes take over, allowing researchers to implement changes to the genetic makeup.
In contrast to earlier instruments that depended on difficult-to-reprogram proteins, CRISPR’s RNA-guided system is more adaptable, simpler to design, and highly accurate. This straightforwardness and precision have enabled CRISPR’s application across medicine, agriculture, manufacturing, and microbiology—such as designing microbes to enhance product yields. However, as this article discusses, with growing capabilities arise increasing ethical dilemmas, particularly concerning germline editing and genetic enhancement.
—
**World’s First Patient of a Personalized CRISPR Treatment**
In February 2025, the inaugural personalized CRISPR treatment was executed for a baby named KJ to address a deficiency in Carbamoyl Phosphate Synthetase 1 (CPS1)—an enzyme crucial for converting ammonia (a byproduct of protein degradation) into urea. A team spearheaded by Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunuru at the Children’s Hospital of Philadelphia created this treatment after extensive research in gene editing and collaboration with other professionals.
Their focus centered on disorders impacting the urea cycle, leading to harmful ammonia accumulation, which can damage organs such as the brain and liver. They customized the treatment specifically to KJ’s variant of CPS1 deficiency based on preclinical studies of similar cases.
Up to this point, the only CRISPR therapies sanctioned by the U.S. FDA have been for more prevalent illnesses like sickle cell disease and beta thalassemia, which impact tens of thousands to hundreds of thousands of individuals. In KJ’s situation, his treatment was devised within a six-month timeframe post-birth, addressing his unique CPS1 variant. The research team developed a base editing therapy administered through lipid nanoparticles to his liver to rectify the dysfunctional enzyme.
The February treatment marked the first of three doses; KJ received the subsequent two in March and April 2025. As of his last administration, he has not experienced significant adverse effects, demonstrates increased tolerance to dietary protein, and requires reduced medication to regulate ammonia levels. Although continuous monitoring is necessary, Ahrens-Nicklas indicates that the outcomes thus far are encouraging.
—
**Ethical Considerations of CRISPR**
Like any pioneering technology, CRISPR prompts intricate ethical inquiries. While its main objective is to modify somatic cells for disease treatment, it can also be utilized on gametes, entering the contentious sphere of germline editing. Modifying DNA that will be passed down to future generations is frequently perceived as unethical—particularly when done for enhancement purposes rather than disease treatment.
In light of these issues, scientists have temporarily banned germline editing until its ethical and social ramifications are clearer. The unpredictability of genetic alterations and the permanence of these changes across generations raise critical questions regarding where to establish boundaries. What began as a ground-breaking concept has evolved into a formidable reality, igniting discussions about who gets to determine its limits.
The high expense and sophisticated infrastructure associated with CRISPR make it more available in affluent, developed countries—especially in the West. As treatments remain costly, access becomes restricted to those with financial means, exacerbating socioeconomic disparities. The potential for using CRISPR to engineer so-called